Efficacy and Safety of Direct Oral Anticoagulant Therapy for Venous Thromboembolism
Rates of recurrence and bleeding were similar between the 3 treatments assessed, but rivaroxaban demonstrated lower mortality rates.
Diagnosis & Disease Information
Guideline Update for Venous Thromboembolism Prophylaxis in Patients With Cancer
The American Society of Clinical Oncology released updates to their guidelines for thromboprophylaxis in patients with cancer.
Clinical Benefit of Oral Anticoagulants May Outweigh Risk of Bleeding in Patients With Atrial Fibrillation
Reinitiation of oral anticoagulant therapy may be warranted for some patients with atrial fibrillation who have a high risk of bleeding.
Revisiting Guidelines on the Use of Direct Oral Anticoagulants in Obese Patients With Atrial Fibrillation
New studies in morbidly obese patients suggest that direct oral anticoagulants may be a safe and efficacious treatment option for thromboembolism and atrial fibrillation.
SAVED Tool Improves Assessment of Venous Thromboembolism Risk in Patients With Multiple Myeloma
Retrospective population-based cohort study is used to validate a new risk assessment tool to identify patients receiving immunomodulatory drugs for multiple myeloma who may be at high risk of VTE.
Direct Oral Anticoagulants Show Similar Efficacy Compared With Warfarin in Morbidly Obese Patients
Incidences of recurrent thromboembolism and major bleeding did not significantly differ between patients receiving DOACs and patients receiving warfarin.
Increased Risk for Venous Thromboembolism in Patients Receiving Anticoagulant Therapy for Pulmonary Embolism
Researchers assessed incidence of recurrent thromboembolism and major bleeding in patients with cancer and incidental pulmonary embolism.
Dabigatran Safe, Effective for Managing VTE in Pediatric Trials
The open label, randomized, multicenter, phase 2b/3 DIVERSITY trial evaluated the efficacy and safety of dabigatran compared with SOC (low molecular weight heparin or vitamin K antagonist) in 240 children.
Rivaroxaban May Be Safe, Effective for Pediatric VTE Treatment, Says Study
Results of the study showed that the rate of symptomatic recurrent VTE – the primary end point – was similar in both treatment groups with 1.2% of patients experiencing a recurrent event in the rivaroxaban group compared with 3.0% in the standard anticoagulation group.
Risk Factors for Recurrent Venous Thromboembolism in Patients With Sickle Cell Disease
Patients with severe sickle cell disease were more than twice as likely to experience recurrent thromboembolism compared with patients with less severe disease.
- Loading...
Loading...
Next post in Thrombotic Disorders
Loading... 
Loading...